Work

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8118

Authors: Eziafa Oduah, Scott Joseph Antonia, Jeffrey J. Clarke, Tom Stinchcombe, Joel Rivera Concepcion, Laura Alder, Cameron Oswalt, Thomas A. D'Amico, David H. Harpole, Betty Caroline Tong, Hai Salfity, Kunal Patel, Kaitlin Bevers, Matthew Galen Hartwig, Xiaofei F. Wang, Neal E. Ready

Institutions: Duke University, Duke Cancer Institute, Duke Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410818009

Cites:

Cited by:

Related to: 10